[
  {
    "ts": null,
    "headline": "Amgen Insiders Sell US$12m Of Stock, Possibly Signalling Caution",
    "summary": "In the last year, many Amgen Inc. ( NASDAQ:AMGN ) insiders sold a substantial stake in the company which may have...",
    "url": "https://finnhub.io/api/news?id=3a790823a1c065ee715c6a257055addce5c3c2542ec8f335a08890f980270207",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751544014,
      "headline": "Amgen Insiders Sell US$12m Of Stock, Possibly Signalling Caution",
      "id": 135735838,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "In the last year, many Amgen Inc. ( NASDAQ:AMGN ) insiders sold a substantial stake in the company which may have...",
      "url": "https://finnhub.io/api/news?id=3a790823a1c065ee715c6a257055addce5c3c2542ec8f335a08890f980270207"
    }
  },
  {
    "ts": null,
    "headline": "PharmaVentures Appoints Samara Ferguson as Vice President to Lead Pricing and Market Access Team",
    "summary": "PharmaVentures is pleased to announce the appointment of Samara Ferguson as Vice President to lead its Pricing and Market Access division, supporting companies in their sell-side, buy-side, and licensing due diligence and deal-making.",
    "url": "https://finnhub.io/api/news?id=3025addee9feb89a638a2fd42b9a6f368a15aefbd9b28ac29a156e89be3960ea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751538960,
      "headline": "PharmaVentures Appoints Samara Ferguson as Vice President to Lead Pricing and Market Access Team",
      "id": 135735839,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "PharmaVentures is pleased to announce the appointment of Samara Ferguson as Vice President to lead its Pricing and Market Access division, supporting companies in their sell-side, buy-side, and licensing due diligence and deal-making.",
      "url": "https://finnhub.io/api/news?id=3025addee9feb89a638a2fd42b9a6f368a15aefbd9b28ac29a156e89be3960ea"
    }
  },
  {
    "ts": null,
    "headline": "Amgen (AMGN) Announces Full Results from Part 1 of the Phase 2 study of MariTide",
    "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. On June 23, the company announced full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), which is a long-acting, peptide-antibody conjugate subcutaneously administered monthly or less frequently. In the Phase 2 study, […]",
    "url": "https://finnhub.io/api/news?id=2f41cf6345231d86a6aee12585de5e6920a45bf0e807d767a9507b3ec4dd5fef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751525252,
      "headline": "Amgen (AMGN) Announces Full Results from Part 1 of the Phase 2 study of MariTide",
      "id": 135735840,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. On June 23, the company announced full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), which is a long-acting, peptide-antibody conjugate subcutaneously administered monthly or less frequently. In the Phase 2 study, […]",
      "url": "https://finnhub.io/api/news?id=2f41cf6345231d86a6aee12585de5e6920a45bf0e807d767a9507b3ec4dd5fef"
    }
  }
]